# US 2010/0168026 A1 · Insulin secretion inducer, and accelerator for increasing the number of pancreatic beta-cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168026 A1
- Document ID: US20100168026A1
- Status: Published application
- Kind: A1
- Application number: 12/669,324
- Filed: 2007-07-20
- Published: 2010-07-01
- Earliest claimed: 2007-07-20
- Assignees: Saitama Medical University
- Inventors: Hideo Toyoshima; Tomotaka Yokoo; Nobuhiro Yamada
- Web page: https://patentgrep.com/patent/US20100168026A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/48: of the pancreatic hormones
- A61P 5/50: for increasing or potentiating the activity of insulin
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2217/052: inducing gain of function
- A01K 2227/105: Murine
- A01K 2267/0325: Animal model for autoimmune diseases
- A01K 2267/0362: Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2799/022: where the vector is derived from an adenovirus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are: an insulin secretion inducer; an insulin secretion-inducing composition; a process for the production of the composition; an accelerator for increasing the number of pancreatic β-cells; a composition for increasing the number of pancreatic β-cells; a process for the production of the composition; and a viral vector for gene therapy. The insulin secretion inducer or the accelerator for increasing the number of pancreatic β-cells comprises a polypeptide having an amino acid sequence encoded by DNA that is known to encode a membrane protein Tm4sf20 (transmembrane 4 L six family member 20) or the like or a fragment of the polypeptide as an active ingredient.

## Claims

### Claim 1

An insulin secretion inducer comprising at least one of the following active ingredients (a) to (f):
(a) a polypeptide having an amino acid sequence encoded by DNA having a base sequence as set forth in SEQ. ID. No. 1 or SEQ. ID. No. 4;
(b) a polypeptide having an insulin secretion inducing action and having an amino acid sequence in which one or a plurality of amino acids has been substituted, deleted and/or added to an amino acid sequence encoded by DNA having a base sequence as set forth in SEQ. ID. No. 1 or SEQ. ID. No. 4;
(c) a fragment of the polypeptide in (a) or (b) having an insulin secretion inducing action;
(d) a polypeptide having an amino acid sequence as set forth in SEQ. ID. No. 3 or SEQ. ID. No. 6;
(e) a polypeptide having an insulin secretion inducing action and having an amino acid sequence in which one or a plurality of amino acids has been substituted, deleted and/or added to an amino acid sequence as set forth in SEQ. ID. No. 3 or SEQ. ID. No. 6; and
(f) a fragment of the polypeptide in (d) or (e) having an insulin secretion inducing action.

### Claim 2 (depends on 1)

The insulin secretion inducer according to claim 1, wherein the polypeptide having the insulin secretion inducing action and having the amino acid sequence in which one or a plurality of amino acids has been substituted, deleted and/or added to the amino acid sequence encoded by DNA having the base sequence as set forth in SEQ. ID. No. 4, is a polypeptide having an amino acid sequence encoded by DNA having a base sequence as set forth in SEQ. ID. No. 7.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The insulin secretion inducer according to claim 1, wherein the polypeptide having the insulin secretion inducing action and having the amino acid sequence in which one or a plurality of amino acids has been substituted, deleted and/or added to the amino acid sequence as set forth in SEQ. ID. No. 6, is a polypeptide having an amino acid sequence as set forth in SEQ. ID. No. 9.

### Claim 5 (depends on 1)

The insulin secretion inducer according to claim 1, wherein a fragment of the polypeptide in (d) or (e) having the insulin secretion inducing action is a polypeptide including an amino acid sequence in SEQ. ID. No. 10, SEQ. ID. No. 11 or SEQ. ID. No. 12.

### Claim at position 6

6-9. (canceled)

### Claim 10

A viral vector for inducing insulin secretion, wherein DNA is integrated as an exogenous gene into a viral vector enabling expression of the exogenous gene, the DNA being DNA having a base sequence as set forth in at least one of SEQ. ID. No. 1, SEQ. ID. No. 4 and SEQ. ID. No. 7, or being DNA capable of hybridizing under stringent conditions with a strand complementary to DNA having the base sequence as set forth in at least one of SEQ. ID. No. 1, SEQ. ID. No. 4 and SEQ. ID. No. 7.

### Claim 11 (depends on 10)

The viral vector according to claim 10, wherein the vector is an adenovirus vector.

### Claim 12

An accelerator for increasing the number of pancreatic β-cells, the accelerator comprising at least one of the following active ingredients (a) to (f):
(a) a polypeptide having an amino acid sequence encoded by DNA having a base sequence as set forth in SEQ. ID. No. 1 or SEQ. ID. No. 4;
(b) a polypeptide having an action of increasing the number of pancreatic β-cells and having an amino acid sequence in which one or a plurality of amino acids has been substituted, deleted and/or added to an amino acid sequence encoded by DNA having a base sequence as set forth in SEQ. ID. No. 1 or SEQ. ID. No. 4;
(c) a fragment of the polypeptide in (a) or (b) having an action of increasing the number of pancreatic β-cells;
(d) a polypeptide having an amino acid sequence as set forth in SEQ. ID. No. 3 or SEQ. ID. No. 6;
(e) a polypeptide having an action of an increasing the number of pancreatic β-cells and having an amino acid sequence in which one or a plurality of amino acids has been substituted, deleted and/or added to an amino acid sequence as set forth in SEQ. ID. No. 3 or SEQ. ID. No. 6; and
(f) a fragment of the polypeptide in (d) or (e) having an action of increasing the number of pancreatic β-cells.

### Claim 13 (depends on 12)

The accelerator for increasing the number of pancreatic β-cells according to claim 12, wherein the polypeptide having the action of increasing the number of pancreatic β-cells and having the amino acid sequence in which one or a plurality of amino acids has been substituted, deleted and/or added to the amino acid sequence encoded by DNA having the base sequence as set forth in SEQ. ID. No. 4, is a polypeptide having an amino acid sequence encoded by DNA having a base sequence as set forth in SEQ. ID. No. 7.

### Claim 14

(canceled)

### Claim 15 (depends on 12)

The accelerator for increasing the number of pancreatic β-cells according to claim 12, wherein the polypeptide having the action of increasing the number of pancreatic β-cells and having the amino acid sequence in which one or a plurality of amino acids has been substituted, deleted and/or added to the amino acid sequence as set forth in SEQ. ID. No. 6, is a polypeptide having an amino acid sequence as set forth in SEQ. ID. No. 9.

### Claim 16 (depends on 12)

The accelerator for increasing the number of pancreatic β-cells according to claim 12, wherein a fragment of the polypeptide in (d) or (e) having the action of increasing the number of pancreatic β-cells is a polypeptide including an amino acid sequence as set forth in SEQ. ID. No. 10, SEQ. ID. No. 11 or SEQ. ID. No. 12.

### Claim at position 14

17-20. (canceled)

### Claim 21

A viral vector for increasing the number of pancreatic β-cells, wherein DNA is integrated as an exogenous gene into a viral vector enabling expression of the exogenous gene, the DNA being DNA having a base sequence as set forth in at least one of SEQ. ID. No. 1, SEQ. ID. No. 4 and SEQ. ID. No. 7, or being DNA capable of hybridizing under stringent conditions with a strand complementary to DNA having the base sequence as set forth in at least one of SEQ. ID. No. 1, SEQ. ID. No. 4 and SEQ. ID. No. 7.

### Claim 22 (depends on 21)

The viral vector according to claim 21, wherein the vector is an adenovirus vector.

### Claim 23

A method of treatment for diseases associated with reduction of insulin secretion capability comprising administering an insulin secretion inducer to a subject in need thereof, the inducer including at least one of the following active ingredients (a) to (f):
(a) a polypeptide having an amino acid sequence encoded by DNA having a base sequence as set forth in SEQ. ID. No. 1 or SEQ. ID. No. 4;
(b) a polypeptide having an insulin secretion inducing action and having an amino acid sequence in which one or a plurality of amino acids has been substituted, deleted and/or added to an amino acid sequence encoded by DNA having a base sequence as set forth in SEQ. ID. No. 1 or SEQ. ID. No. 4;
(c) a fragment of the polypeptide in (a) or (b) having an insulin secretion inducing action;
(d) a polypeptide having an amino acid sequence as set forth in SEQ. ID. No. 3 or SEQ. ID. No. 6;
(e) a polypeptide having an insulin secretion inducing action and having an amino acid sequence in which one or a plurality of amino acids has been substituted, deleted and/or added to an amino acid sequence as set forth in SEQ. ID. No. 3 or SEQ. ID. No. 6; and
(f) a fragment of the polypeptide in (d) or (e) having an insulin secretion inducing action.

### Claim 24

A method of treatment for diseases associated with reduction or necrosis in pancreatic β-cells comprising administering an accelerator for increasing the number of pancreatic β-cells to a subject in need thereof, the accelerator including at least one of the following active ingredients (a) to (f):
(a) a polypeptide having an amino acid sequence encoded by DNA having a base sequence as set forth in SEQ. ID. No. 1 or SEQ. ID. No. 4;
(b) a polypeptide having an insulin secretion inducing action and having an amino acid sequence in which one or a plurality of amino acids has been substituted, deleted and/or added to an amino acid sequence encoded by DNA having a base sequence as set forth in SEQ. ID. No. 1 or SEQ. ID. No. 4;
(c) a fragment of the polypeptide in (a) or (b) having an insulin secretion inducing action;
(d) a polypeptide having an amino acid sequence as set forth in SEQ. ID. No. 3 or SEQ. ID. No. 6;
(e) a polypeptide having an insulin secretion inducing action and having an amino acid sequence in which one or a plurality of amino acids has been substituted, deleted and/or added to an amino acid sequence as set forth in SEQ. ID. No. 3 or SEQ. ID. No. 6; and
(f) a fragment of the polypeptide in (d) or (e) having an insulin secretion inducing action.
